{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"18.1","upperLimit":"34.8","value":"28"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"57"}],"units":"Participants"}],"description":"PFS: Time from study entry to progression/relapse or death from study entry to death of any cause, assessed using International Myeloma Working Group Response Definitions. Progressive Disease (PD): One of the following criteria must be met: a. Increase of 25% or greater in serum M protein (absolute increase greater or equal to 0.5g/dl); b. Increase of 25% or greater in urine M protein (absolute increase greater than 200 mg/24h); c. Increase of 25% or greater in the difference between the involved and uninvolved free light chain (absolute increase greater than 10 mg/dl); d. Increase of 25% or greater in bone marrow plasma cell percentage (absolute percent greater than 5% in case the patient was in CR and 10% otherwise); i.e. Definite development of new bone lesions or soft tissue plasmacytomas, or increase in the size of existing plasmacytomas by greater or equal to 25%. Development of hypercalcemia (serum calcium \\> 11.5 mg/dl) attributable only to the plasma cell dyscrasia.","dispersionType":"95% Confidence Interval","groups":[{"description":"Induction Phase Followed by Maintenance Therapy.\n\nPatients received lenalidomide 25 mg orally on days 1-21, dexamethasone 40 mg orally on days on 1-4, and Pegylated Liposomal Doxorubicin (PLD) 40 mg/m\\^2 intravenously on day 1 (reduced to 30 mg/m\\^2 after the initial 29 patients were treated). Cycles were repeated every 28 days.\n\nAt the best response (4-8 cycles of induction), patients could proceed with either high-dose therapy or maintenance with lenalidomide and dexamethasone at the tolerated doses on the same schedule until disease progression.\n\nDd-R: Lenalidomide (Revlimid®) combined with Pegylated Liposomal Doxorubicin (Doxil®) and Dexamethasone (Decadron®) as outlined in the Detailed Description.","id":"OG000","title":"Induction and Maintenance Therapy"}],"paramType":"MEDIAN","populationDescription":"All participants","reportingStatus":"POSTED","timeFrame":"24 Months","title":"Median Progression Free Survival (PFS) in Months","type":"SECONDARY","unitOfMeasure":"months"}